Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

FGEN.US Logo

FGEN.US - Current Price

$9.07

Company Information

▼
Company Name
FibroGen Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US31572Q8087
CIK: 0000921299
CUSIP: 31572Q808
Currency: USD
Full Time Employees: 225
Phone: 415 978 1200
Website: https://www.fibrogen.com
Fiscal Year End: December
IPO Date: Nov 14, 2014
Description:

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Address:

350 Bay Street, San Francisco, CA, United States, 94133

Directors & Officers

▼
Name Title Year Born
Mr. Thane Wettig CEO & Director 1965
Mr. David DeLucia Senior VP & CFO 1989
Mr. John Alden Corporate Secretary & General Counsel NA
Ms. Gaia Vasiliver-Shamis Director of IR & Communications - LifeSci Advisors NA

Shares Statistics

▼
Shares Outstanding: 4.05M
Shares Float: 3.58M
% Insiders: 165.60%
% Institutions: 2,801.00%
Short % Float: 3.31%

Valuation Metrics

▼
Enterprise Value: $87.06M
Trailing P/E: 0.00
Forward P/E: 61.35

Financial Highlights

▼
Market Cap: $39.28M
EBITDA: $-58.06M
PEG Ratio: $0.00
Book Value: $-4.21
Earnings/Share: $-12.85
Profit Margin: 2,598.87%
Operating Margin: -499.07%
ROA (TTM): -18.42%
ROE (TTM): -1,015.79%
Revenue (TTM): $8.30M
Revenue/Share (TTM): $2.05
Earnings Growth (YOY): 53.60%
Revenue Growth (YOY): 774.80%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 -3.25 -0.10 N/A -332,105.26%
Jun 30, 2025 -3.39 -0.09 N/A -366,666.67%
Mar 31, 2025 0.05 0.02 N/A 15,000.00%
Dec 31, 2024 -0.08 -0.20 N/A 6,000.00%
Sep 30, 2024 0.01 -0.30 N/A 10,486.67%
Jun 30, 2024 -0.16 -0.32 N/A 5,000.00%
Mar 31, 2024 -0.33 -0.42 N/A 2,142.86%
Dec 31, 2023 -0.57 -0.42 N/A -3,571.43%
Sep 30, 2023 -0.52 -0.68 N/A 2,352.94%
Jun 30, 2023 -0.90 -0.70 N/A -2,857.14%
Mar 31, 2023 -0.81 -0.75 N/A -800.00%
Dec 31, 2022 -0.70 -0.94 N/A 2,553.19%
Sep 30, 2022 -0.98 -0.81 N/A -2,098.77%
Jun 30, 2022 -0.78 -0.94 N/A 1,702.13%
Mar 31, 2022 -0.68 -0.83 N/A 1,807.23%
Dec 31, 2021 -1.45 -0.66 N/A -11,969.70%
Sep 30, 2021 0.54 -0.01 N/A 550,000.00%
Jun 30, 2021 -1.45 -0.48 N/A -20,208.33%
Mar 31, 2021 -0.78 -0.87 N/A 1,034.48%
Dec 31, 2020 -0.64 -0.24 N/A -16,666.67%
Sep 30, 2020 0.35 -0.80 N/A 14,375.00%
Jun 30, 2020 -0.95 -0.64 N/A -4,843.75%
Mar 31, 2020 -0.89 -0.39 N/A -12,820.51%
Dec 31, 2019 -1.12 -0.59 N/A -8,983.05%
Sep 30, 2019 -0.57 -0.55 N/A -363.64%
Jun 30, 2019 1.26 -0.51 N/A 34,705.88%
Mar 31, 2019 -0.53 -0.67 N/A 2,089.55%
Dec 31, 2018 0.25 -0.10 N/A 35,000.00%
Sep 30, 2018 -0.50 -0.35 N/A -4,285.71%
Jun 30, 2018 -0.28 -0.59 N/A 5,254.24%
Mar 31, 2018 -0.50 -0.51 N/A 196.08%
Dec 31, 2017 -0.27 -0.28 N/A 357.14%
Sep 30, 2017 -0.50 -0.37 N/A -3,513.51%
Jun 30, 2017 -0.48 -0.47 N/A -212.77%
Mar 31, 2017 -0.52 -0.49 N/A -612.24%
Dec 31, 2016 -0.54 -0.53 N/A -188.68%
Sep 30, 2016 -0.38 -0.60 N/A 3,666.67%
Jun 30, 2016 0.35 0.36 N/A -277.78%
Mar 31, 2016 -0.45 -0.56 N/A 1,964.29%
Dec 31, 2015 -0.85 -0.41 N/A -10,731.71%
Sep 30, 2015 -0.74 -0.59 N/A -2,542.37%
Jun 30, 2015 0.83 0.73 N/A 1,369.86%
Mar 31, 2015 -0.78 -0.52 N/A -5,000.00%
Dec 31, 2014 -0.82 -0.90 N/A 888.89%
Sep 30, 2014 -0.33 N/A N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $50.48M $N/A $214.53M $398.16M $-225.60M
2023-12-31 $113.69M $N/A $423.53M $585.73M $-204.17M
2022-12-31 $155.70M $N/A $610.09M $611.57M $-21.45M
2021-12-31 $171.22M $N/A $773.82M $544.71M $209.15M
2020-12-31 $678.39M $N/A $826.84M $385.39M $422.18M
2019-12-31 $126.27M $N/A $857.40M $321.99M $516.14M
2018-12-31 $89.26M $N/A $880.60M $352.13M $509.20M
2017-12-31 $673.66M $N/A $898.65M $316.20M $563.18M
2016-12-31 $173.78M $N/A $469.55M $294.44M $155.84M
2015-12-31 $153.32M $N/A $470.57M $273.75M $177.55M
2014-12-31 $165.46M $N/A $483.53M $242.85M $221.41M
2013-12-31 $76.33M $N/A $296.95M $189.35M $79.73M
2012-12-31 $38.87M $N/A $265.59M $143.40M $94.48M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jun 30, 2025 N/A N/A N/A N/A N/A N/A
Mar 24, 2025 N/A N/A N/A N/A N/A N/A
Mar 20, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist